{"entity":{"id":"nct06491472","kind":"trial","name":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of ivonescimab, gemcitabine and nab-paclitaxel in pancreatic cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.","summary":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer is a phase 2, interventional study registered as NCT06491472 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 36 participants, started 2024-07-15 and due to reach its primary completion in 2026-07-15. Interventions recorded: Ivonescimab; Gemcitabine; Nab paclitaxel; SBRT. Conditions listed: Pancreatic Cancer. Primary outcome: Objective Response Rate(ORR). Pancreatic eligibility wording from the registry: \"* Histologically- or cytologically-confirmed diagnosis of pancreatic ductal adenocarcinoma (including adenosquamous carcinoma)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06491472","url":"https://clinicaltrials.gov/study/NCT06491472"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","sbrt"],"targets":[],"drugs":["ivonescimab","gemcitabine","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06491472","phase":"2","setting":"Efficacy and Safety of Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer：A Single-arm, Open-label, Phase II Clinical Study","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06491472/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}